Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

After trailing broader equities over the past few years, will the healthcare sector finally bounce back in 2026? It's hard to ...

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

In this video, we explore China Gate, a Chinese food restaurant in Los Angeles. Join us as we review their menu and share our ...

Rockstar Eater explores Le Grand restaurant in Downtown Los Angeles, which features a $49.99 Unlimited Tasting Experience.

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Steel is a cyclical sector, and several catalysts could propel Nucor stock even higher through the cycle. However, there are ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...